We would like to inform you that the Board of Directors has at its meeting held today, i.e. Saturday, May 30, 2026, inter-alia, considered and approved: 1. the Standalone and Consolidated ....
PANACEABIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Panacea Biotec's Board approved FY 2025-26 audited results showing standalone revenue grew 33% to ₹41,349 Lakh, but net loss widened to ₹2,988 Lakh due to higher material costs. Consolidated revenue rose 14% to ₹63,977 Lakh with net loss narrowing to ₹716 Lakh. The company reported exceptional income of ₹1,950 Lakh from Apotex settlement and deferred brand sale consideration. No dividend was declared due to losses. Mr. Rajinder Singh Manku was appointed as non-executive independent director for 5 years from July 1, 2026. The auditors issued an unmodified opinion.
Despite revenue growth, persistent losses and negative retained earnings (standalone: ₹21,782 Lakh) raise going concern questions. The company's reliance on exceptional items and vaccines business volatility may concern investors.